 EMERYVILLE, Calif.--BUSINESS WIRE--Adamas Pharmaceuticals, Inc. Nasdaq: ADMS, a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology AAN 73rd Annual Meeting. One of the presentations will focus on GOCOVRI amantadine extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesi 